Hong Zhi GaoKeiko KobayashiAyako TabataHideaki TsugeMikio IijimaTomotsugu YasudaH. Serap KalkanogluAli DursunAysegul TokatliTurgay CoskunFriedrich K. TrefzDaniela SkladalHanna MandelJoerg SeidelSoichi KodamaSeiko ShiraneTakafumi IchidaShigeru MakinoMakoto YoshinoJong Hon KangMasashi MizuguchiBruce A. BarshopShohei FuchinoueSara SenecaSusan ZeesmanIna KnerrMargarita RodésPornswan WasantIchiro YoshidaLinda De MeirleirAbdul Md JalilLaila BegumMasahisa HoriuchiNobuhiko KatunumaShiro NakagawaTakeyori SahekiKagoshima UniversityTokushima Bunri UniversityHacettepe University, Faculty of MedicineUniversitat TubingenUniversity of InnsbruckRambam Health Care Campus IsraelFriedrich Schiller Universitat JenaHimeji Red Cross HospitalNiigata National HospitalNiigata University School of MedicineUji Tokushukai HospitalKurume University School of MedicineTeine Keijinkai HospitalJichi Medical UniversityUniversity of California, San Diego, School of MedicineTokyo Women's Medical UniversityUniversitair Ziekenhuis BrusselDepartment of PediatricsFriedrich-Alexander-Universität Erlangen-NürnbergInstitut de Bioquimica Clinica, BarcelonaMahidol UniversityVrije Universiteit Brussel2018-07-242018-07-242003-07-16Human Mutation. Vol.22, No.1 (2003), 24-34105977942-s2.0-0038385026https://repository.li.mahidol.ac.th/handle/123456789/20709Classical citrullinemia (CTLN1), a rare autosomal recessive disorder, is caused by mutations of the argininosuccinate synthetase (ASS) gene, localized on chromosome 9q34.1. ASS functions as a rate-limiting enzyme in the urea cycle. Previously, we identified 32 mutations in the ASS gene of CTLN1 patients mainly in Japan and the United States, and to date 34 different mutations have been described in 50 families worldwide. In the present study, we report ASS mutations detected in 35 additional CTLN1 families from 11 countries. By analyzing the entire coding sequence and the intron-exon boundaries of the ASS gene using RT-PCR and/or genomic DNA-PCR, we have identified 16 novel mutations (two different 1-bp deletions, a 67-bp insertion, and 13 missense) and have detected 12 known mutations. Altogether, 50 different mutations (seven deletion, three splice site, one duplication, two nonsense, and 37 missense) in 85 CTLN1 families were identified. On the basis of primary sequence comparisons with the crystal structure of E. coli ASS protein, it may be concluded that any of the 37 missense mutations found at 30 different positions led to structural and functional impairments of the human ASS protein. It has been found that three mutations are particularly frequent: IVS6-2A>G in 23 families (Japan: 20 and Korea: three), G390R in 18 families (Turkey: six, U.S.: five, Spain: three, Israel: one, Austria: one, Canada: one, and Bolivia: one), and R304W in 10 families (Japan: nine and Turkey: one). Most mutations of the ASS gene are "private" and are distributed throughout the gene, except for exons 5 and 12-14. It seems that the clinical course of the patients with truncated mutations or the G390R mutation is early,onset/severe. The phenotype of the patients with certain missense mutations (G362V or W179R) is more late-onset/mild. Eight patients with R86H, A118T, R265H, or K310R mutations were adult/late-onset and four of them showed severe symptoms during pregnancy or postpartum. However, it is still difficult to prove the genotype-phenotype correlation, because many patients were compound heterozygotes (with two different mutations), lived in different environments at the time of diagnosis, and/or had several treatment regimes or various knowledge of the disease. © 2003 Wiley-Liss, Inc.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1002/humu.10230